|1.||Jasani, B: 3 articles (05/2009 - 01/2003)|
|2.||Adams, M: 3 articles (05/2009 - 01/2003)|
|3.||Navabi, H: 3 articles (05/2009 - 01/2003)|
|4.||Ichinohe, Takeshi: 2 articles (10/2009 - 09/2007)|
|5.||Tashiro, Masato: 2 articles (10/2009 - 09/2007)|
|6.||Sata, Tetsutaro: 2 articles (10/2009 - 09/2007)|
|7.||Hasegawa, Hideki: 2 articles (10/2009 - 09/2007)|
|8.||Mason, M: 2 articles (01/2009 - 01/2003)|
|9.||Donninger, C: 2 articles (01/2009 - 01/2003)|
|10.||De Clercq, Erik: 2 articles (01/2004 - 02/2003)|
01/01/1988 - "Collectively, these results indicate that rIFN-A, r-IFN-G, ampligen and CL246,738 may be useful in prophylactic or early therapeutic treatment of several serious virus infections. "
01/01/2004 - "In July 2001 Hemispherx Biopharma announced that it had formed a strategic alliance with Empire Health Resources for clinical trials of Ampligen in the treatment of HIV and hepatitis C virus infections. "
07/01/1994 - "Given these in vitro findings, and the low frequency of toxicity reported with the use of Ampligen, clinical trials of this drug in patients with evidence of reactivated HHV-6 infection would seem to be warranted."
07/01/1994 - "When lower concentrations of Ampligen (10 and 50 micrograms/ml) were used, only pretreatment of cells, with Ampligen, followed by virus infection and carrying the infected cells with Ampligen, significantly inhibited HHV-6 infection (83.7 and 89.1% respectively). "
07/01/1994 - "When cells were pretreated with Ampligen (concentrations of 100 or 200 micrograms/ml) prior to infection or treated shortly after infection, viral replication was inhibited by 46-98%. "
01/01/2004 - "Even when start of treatment with Ampligen was delayed until day 2 postinfection, a time at which lesions had already appeared in untreated control animals, a marked protective effect on the development of viral myocarditis (as assessed at day 6 postinfection) was still noted."
01/01/2004 - "Whereas the electrocardiograms for untreated mice with myocarditis were severely disturbed, the electrocardiographic parameters were normalized in Ampligen- and poly(IC)-treated mice. "
01/01/2004 - "Ampligen at 20 mg/kg of body weight/day was able to reduce the severity of virus-induced myocarditis, as assessed by morphometric analysis, by 98% (P = 3.0 x 10(-8)). "
01/01/2004 - "We evaluated the efficacy of the interferon inducer Ampligen on coxsackie B3 virus-induced myocarditis in C3H/HeNHsd mice. "
01/01/2004 - "Researchers at the Rega Institute in Belgium have published results from an animal study demonstrating that Ampligen was superior at protecting mice against coxsackie B3 virus-induced myocarditis compared with pegylated interferon. "
|3.||AIDS-Related Complex (ARC)
04/18/1987 - "Thus, combined therapy with ampligen and AZT can be expected to be more beneficial than AZT alone to patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex since AZT regimens that seem to be clinically effective are associated with considerable toxicity."
10/01/1992 - "Ampligen, poly(I)n:poly(C12U)n, was administered intravenously to 39 human immunodeficiency virus (HIV)-infected subjects, asymptomatic or with early AIDS-related complex (ARC) and with CD4+ cell counts less than 500/mm3 in a phase I dose-escalation study. "
06/06/1987 - "10 patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or lymphadenopathy syndrome (LAS) were given 200-250 mg ampligen, a mismatched double-stranded (ds) RNA with in-vitro antiviral activity against human immunodeficiency virus (HIV), twice a week for up to 18 weeks, without side-effects or toxicity. "
06/06/1987 - "Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex."
|4.||Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
01/01/2004 - "Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen for the treatment of chronic fatigue syndrome; the first stage of th;) for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared. "
01/01/2004 - "Bioclones has initiated clinical studies with Ampligen for the treatment of chronic fatigue syndrome in Australia. "
01/01/2004 - "Ampligen is available for severe chronic fatigue syndrome on a named patient, cost-recovery basis in South Africa. "
01/01/2004 - "In the meantime, Ampligen has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma). "
01/01/2004 - "In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome. "
|4.||Interferon-alpha (Interferon Alfa)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)
|5.||Dilatation and Curettage (D&C)